Şebnem Şenol Akar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Şebnem Şenol Akar has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Deniz Özer
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Manisa Celal Bayar University, Hafsa Sultan Hospital, Manisa, Turkiye
5 shared publications - Sinem Akçalı
Manisa Celal Bayar Univ, Dept Med Microbiol, Fac Med, Manisa, Turkey
5 shared publications - Çiğdem Banu Çetin
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Manisa Celal Bayar University, Hafsa Sultan Hospital, Manisa, Turkiye
5 shared publications - Erhan Eser
Manisa Celal Bayar University
4 shared publications - Ferya Karadağ Yalçın
Manisa Celal Bayar Univ, Hafsa Sultan Training & Res Hosp, Hlth Serv Directorate, Fac Med, Manisa, Turkiye
4 shared publications - Kübra Çiçek
Hatay Dörtyol İlçe Sağlık Müdürlüğü
3 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by Springer Nature in BMC Infectious Diseases
A Tularemia cluster in Manisa, Türkiye: clinical characteristics and investigation of a probable waterborne source
Background: Tularemia is a re-emerging zoonotic disease caused by Francisella tularensis. In Türkiye, water-associated transmission is an important epidemiological pattern and oropharyngeal disease is common. This study aimed to describe the clinical characteristics of a tularemia cluster identified in Manisa, western Türkiye, and to evaluate the epidemiological and environmental findings supporting a probable waterborne source. Methods: This retrospective, observational, two-center study included 13 adult patients with clinically compatible tularemia and a single positive microagglutination test (MAT) titer of ≥ 1:160 diagnosed between January and May 2025. Demographic, epidemiological, clinical, laboratory, radiological, cytopathological, treatment, and outcome data were retrospectively collected. Twelve patients from Alaşehir reported natural spring-water consumption within the same local area, whereas one patient resided in Demirci and had a separate exposure history. Following recognition of the cluster, an environmental investigation was conducted under the coordination of the Provincial Directorate of Health. Results: Thirteen patients were included. The median age was 33 years (range, 21–73 years), and eight (61.5%) were female. Twelve patients (92.3%) resided in rural Alaşehir and reported natural spring-water consumption within the same local area; one patient resided in Demirci and was not epidemiologically linked to that exposure. The oropharyngeal form was the most common presentation (10/13, 76.9%), followed by the glandular form (3/13, 23.1%). Cervical lymphadenopathy was present in all patients, and imaging frequently demonstrated necrosis, liquefaction, abscess formation, or surrounding soft-tissue involvement. Before referral, most patients had received antimicrobial therapy that was ineffective against tularemia. Because this was a selected tertiary-care referral cohort with persistent symptoms and/or complicated lymphadenopathy, treatment was individualized according to disease duration and clinical response; drainage was required in selected patients. All patients achieved clinical recovery. A stored natural spring-water sample obtained from a household in Alaşehir was reported culture-positive for F. tularensis by the National Reference Laboratory. Molecular confirmation or typing linking the environmental finding to the human cases was not available. Conclusions: This cluster highlights the importance of considering tularemia in patients with persistent cervical lymphadenopathy and tonsillopharyngitis unresponsive to beta-lactam antibiotics, particularly in rural settings with natural spring-water exposure. The shared exposure among the Alaşehir cases and the culture-positive environmental sample support a probable waterborne source; however, the absence of direct microbiological confirmation of the human cases and molecular linkage prevents definitive attribution of the transmission chain.
- 26 September 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessA Tularemia cluster in Manisa, Türkiye: clinical characteristics and investigation of a probable waterborne source
Background: Tularemia is a re-emerging zoonotic disease caused by Francisella tularensis. In Türkiye, water-associated transmission is an important epidemiological pattern and oropharyngeal disease is common. This study aimed to describe the clinical characteristics of a tularemia cluster identified in Manisa, western Türkiye, and to evaluate the epidemiological and environmental findings supporting a probable waterborne source. Methods: This retrospective, observational, two-center study included 13 adult patients with clinically compatible tularemia and a single positive microagglutination test (MAT) titer of ≥ 1:160 diagnosed between January and May 2025. Demographic, epidemiological, clinical, laboratory, radiological, cytopathological, treatment, and outcome data were retrospectively collected. Twelve patients from Alaşehir reported natural spring-water consumption within the same local area, whereas one patient resided in Demirci and had a separate exposure history. Following recognition of the cluster, an environmental investigation was conducted under the coordination of the Provincial Directorate of Health. Results: Thirteen patients were included. The median age was 33 years (range, 21–73 years), and eight (61.5%) were female. Twelve patients (92.3%) resided in rural Alaşehir and reported natural spring-water consumption within the same local area; one patient resided in Demirci and was not epidemiologically linked to that exposure. The oropharyngeal form was the most common presentation (10/13, 76.9%), followed by the glandular form (3/13, 23.1%). Cervical lymphadenopathy was present in all patients, and imaging frequently demonstrated necrosis, liquefaction, abscess formation, or surrounding soft-tissue involvement. Before referral, most patients had received antimicrobial therapy that was ineffective against tularemia. Because this was a selected tertiary-care referral cohort with persistent symptoms and/or complicated lymphadenopathy, treatment was individualized according to disease duration and clinical response; drainage was required in selected patients. All patients achieved clinical recovery. A stored natural spring-water sample obtained from a household in Alaşehir was reported culture-positive for F. tularensis by the National Reference Laboratory. Molecular confirmation or typing linking the environmental finding to the human cases was not available. Conclusions: This cluster highlights the importance of considering tularemia in patients with persistent cervical lymphadenopathy and tonsillopharyngitis unresponsive to beta-lactam antibiotics, particularly in rural settings with natural spring-water exposure. The shared exposure among the Alaşehir cases and the culture-positive environmental sample support a probable waterborne source; however, the absence of direct microbiological confirmation of the human cases and molecular linkage prevents definitive attribution of the transmission chain.
- 17 February 2026
- Published by Academician Publishing
- p. 125-134
Spinal Enfeksiyonlarda Konservatif Tedavinin Komplikasyonları
- 17 February 2026
- Published by Academician Publishing
- p. 125-134
Spinal Enfeksiyonlarda Konservatif Tedavinin Komplikasyonları
- 17 February 2026
- Published by Academician Publishing
- p. 61-80
Spesifik Enfeksiyonlarda Konservatif Tedavi
- 17 February 2026
- Published by Academician Publishing
- p. 61-80
Spesifik Enfeksiyonlarda Konservatif Tedavi
- 27 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 47 (4) , 204-208
Unpleasant Souvenir: Imported Plasmodium falciparum Malaria in Türkiye
Each year, approximately 125 million people visit malaria-endemic countries. This study aimed to investigate the clinical characteristics of imported Plasmodium falciparum malaria infections in Türkiye. The study included patients diagnosed with P. falciparum malaria between 1996 and 2022. A retrospective evaluation was conducted on whole blood samples and/or blood smears, as well as detailed medical histories, clinical manifestations, and laboratory findings. A total of 131 imported cases of P. falciparum were included in the study. Among the patients, 121 were male. Of these, 101 had traveled to Africa, while 30 had visited Asia. Among the patients, 109 were returned travelers, and 22 were refugees/migrants. Early trophozoites were observed in all patients, while gametocytes were detected in 30 patients. Cerebral malaria developed in 15 patients, resulting in the death of two individuals. Additionally, 10 patients received preventive chemoprophylaxis. Turkey is situated on migration routes that connect two continents to Europe, where more than 95% of the global malaria burden exists. The importation of malaria through returned travelers poses a risk of malaria reintroduction in our country, given the presence of suitable vectors, climate conditions, and environmental factors. Importantly, 30 patients (22.9%) exhibited gametocyte forms of P. falciparum, which have the potential to infect Anopheles species, thus establishing a basis for local malaria transmission.
- 27 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 47 (4) , 204-208
Unpleasant Souvenir: Imported Plasmodium falciparum Malaria in Türkiye
Each year, approximately 125 million people visit malaria-endemic countries. This study aimed to investigate the clinical characteristics of imported Plasmodium falciparum malaria infections in Türkiye. The study included patients diagnosed with P. falciparum malaria between 1996 and 2022. A retrospective evaluation was conducted on whole blood samples and/or blood smears, as well as detailed medical histories, clinical manifestations, and laboratory findings. A total of 131 imported cases of P. falciparum were included in the study. Among the patients, 121 were male. Of these, 101 had traveled to Africa, while 30 had visited Asia. Among the patients, 109 were returned travelers, and 22 were refugees/migrants. Early trophozoites were observed in all patients, while gametocytes were detected in 30 patients. Cerebral malaria developed in 15 patients, resulting in the death of two individuals. Additionally, 10 patients received preventive chemoprophylaxis. Turkey is situated on migration routes that connect two continents to Europe, where more than 95% of the global malaria burden exists. The importation of malaria through returned travelers poses a risk of malaria reintroduction in our country, given the presence of suitable vectors, climate conditions, and environmental factors. Importantly, 30 patients (22.9%) exhibited gametocyte forms of P. falciparum, which have the potential to infect Anopheles species, thus establishing a basis for local malaria transmission.
- 15 April 2023
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 57 (2) , 238-251
Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers
This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioN- Tech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in T0rkiye. Coro- navirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees fol- lowed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Work-ers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heter- ologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 +/- 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI=-56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI=-30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consist-ing of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three dos-es of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.
- 15 April 2023
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 57 (2) , 238-251
Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers
This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioN- Tech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in T0rkiye. Coro- navirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees fol- lowed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Work-ers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heter- ologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 +/- 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI=-56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI=-30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consist-ing of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three dos-es of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.
- 25 April 2022
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 56 (2) , 274-287
Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği
In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 +/- 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year.
- 25 April 2022
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 56 (2) , 274-287
Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği
In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 +/- 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year.
- Open Access
- 1 April 2022
- Published by Turkish Journal of Public Health in Türkiye Halk Sağlığı Dergisi
- Vol. 20 (1) , 117-128
Türkiye’de bir üçüncü basamak hastanede sağlık çalışanlarında SARS-CoV-2 seroprevalansı
Objective: The aim of this study is to investigate the previous four months (March-July 2020) SARS-CoV-2 infection rate, seroprevalence and the variables affecting these in HCWs in a university hospital. Methods: The present study is a SARS-CoV-2 seroprevalence study on HCWs working in a tertiary hospital during the first stage (March-July 2020) of the outbreak in Turkey. The presence of IgM and IgG antibodies against the spike structure of the virus was investigated by the chemiluminescent enzyme immunoassay (CLIA) method using the commercial antibody kit (COV2T, Siemens®, Tarrytown, NY, US). Participants’ socio-demographic characteristics, health status, lifestyle, risky occupational and social and personal protective equipment (PPE) usage were independent variables of the study. Chi-square test and Fisher’s exact test were used in univariate analyzes, and accepted type 1 error value was 0.05. The analyzes were made using the SPSS 23.0 package program. Results: 1177 out of a total of 1702 health workers participated in the study. Participation rate was 69.1% . The mean age of the study group was 35.3 ± 9.8 and 62.7% were females. SARS-CoV-2 infection rate detected by nucleic acid amplification test (NAAT-PCR) or antibody test (Elisa) was (18/1177) 1.5%; The seroprevalence of SARS-CoV-2 was 1.01%. 17% of the entire SARS-CoV-2 cases were asymptomatic. The highest infection prevalence was significantly higher in auxiliary health workers (3.7%) compared to other groups. The presence of symptoms HCW’s and their family members that did not exist before in the last 15 days, being overweight or obese and consulting as contacted person in survelliance unit were significantly related to having SARS-CoV-2 infection (p
- 1 April 2022
- Published by Turkish Journal of Public Health in Türkiye Halk Sağlığı Dergisi
- Vol. 20 (1) , 117-128
Open AccessTürkiye’de bir üçüncü basamak hastanede sağlık çalışanlarında SARS-CoV-2 seroprevalansı
Objective: The aim of this study is to investigate the previous four months (March-July 2020) SARS-CoV-2 infection rate, seroprevalence and the variables affecting these in HCWs in a university hospital. Methods: The present study is a SARS-CoV-2 seroprevalence study on HCWs working in a tertiary hospital during the first stage (March-July 2020) of the outbreak in Turkey. The presence of IgM and IgG antibodies against the spike structure of the virus was investigated by the chemiluminescent enzyme immunoassay (CLIA) method using the commercial antibody kit (COV2T, Siemens®, Tarrytown, NY, US). Participants’ socio-demographic characteristics, health status, lifestyle, risky occupational and social and personal protective equipment (PPE) usage were independent variables of the study. Chi-square test and Fisher’s exact test were used in univariate analyzes, and accepted type 1 error value was 0.05. The analyzes were made using the SPSS 23.0 package program. Results: 1177 out of a total of 1702 health workers participated in the study. Participation rate was 69.1% . The mean age of the study group was 35.3 ± 9.8 and 62.7% were females. SARS-CoV-2 infection rate detected by nucleic acid amplification test (NAAT-PCR) or antibody test (Elisa) was (18/1177) 1.5%; The seroprevalence of SARS-CoV-2 was 1.01%. 17% of the entire SARS-CoV-2 cases were asymptomatic. The highest infection prevalence was significantly higher in auxiliary health workers (3.7%) compared to other groups. The presence of symptoms HCW’s and their family members that did not exist before in the last 15 days, being overweight or obese and consulting as contacted person in survelliance unit were significantly related to having SARS-CoV-2 infection (p
- 31 March 2022
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (1) , 136-142
Antifungal Kullanımının Değerlendirilmesi: Türkiyenin Batısına Ait Çok Merkezli Nokta Prevelans Çalışması
Giriş ve Amaç: Son yıllarda yeni ajanların da kullanıma girmesiyle birlikte antifungal tüketimi giderek artmıştır. Bu durum, direnç gelişimi konusunda endişelere neden olmaktadır. Ülkemizde antifungal tüketimine ait veriler oldukça sınırlıdır. Bu çalışmada, Türkiye’nin batısındaki yedi üniversite hastanesinde yatan hastalarda antifungal kullanımının değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışma ekibi tarafından hazırlanan antifungal kullanım formu, tüm merkezler tarafından, aynı gün içinde, antifungal kullanan tüm hastalar için, nokta prevalans yöntemi ile dolduruldu, elde edilen veriler SPSS programı ile değerlendirildi. Bulgular: Toplam hasta sayısı 4969 idi. Hastaların 112(%2.2) ’si antifungal tedavi almaktaydı. Bu 112 hastanın verileri değerlendirildiğinde; antifungal kullanan hastaların 56 (%50)’sı hematoloji-onkoloji, 20 (%17,8)’si yoğun bakım (YB), 23 (%20,5)’ü dahili bilimler ve 13 (%11,6)’ü cerrahi bilimlerde izlenmekteydi. En sık kullanılan antifungal flukonazol [44(%39,3)] olup %34.1’i profilaksi amacı ile kullanılmaktaydı. Tedavilerin %38’i hedefe yönelik, %26.8’i ampirik ve %18,8’i preemptif olarak tanımlanmıştı. Yattığı kliniğe göre tedavi endikasyonları değerlendirildiğinde en çok pre-emptif antifungal kullanımı hemato-onkoloji kliniğinde %71.4 (15/21) görülürken ampirik tedavi en çok yoğun bakımlarda %50 olmuştur. Sonuç: Çalışmamızda antifungal tüketim oranı %2.2 olup, antifungal ajanlar daha çok hematoloji ve dahili birimlerde kullanılmıştır. Antifungal tedaviye başlama nedeni en fazla 'kanıtlanmış mantar infeksiyonu' olarak gözlenmiştir. En sık izole edilen patojenler Candida türleri olmasına rağmen, antifungal ajan seçimi hastanın yattığı kliniğe bağlıdır. Antifungal tüketim açısından yedi merkez arasında anlamlı fark gözlenmemiştir. Bu durum ülkemizdeki antifungal kullanımı politikası ile açıklanabilir. Bu sonuçlara bağlı olarak her hastane kendi verilerini izlemelidir ve izole edilen fungal patojenlere göre antifungal tedavi politikası geliştirilmelidir.
- 31 March 2022
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 9 (1) , 136-142
Antifungal Kullanımının Değerlendirilmesi: Türkiyenin Batısına Ait Çok Merkezli Nokta Prevelans Çalışması
Giriş ve Amaç: Son yıllarda yeni ajanların da kullanıma girmesiyle birlikte antifungal tüketimi giderek artmıştır. Bu durum, direnç gelişimi konusunda endişelere neden olmaktadır. Ülkemizde antifungal tüketimine ait veriler oldukça sınırlıdır. Bu çalışmada, Türkiye’nin batısındaki yedi üniversite hastanesinde yatan hastalarda antifungal kullanımının değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışma ekibi tarafından hazırlanan antifungal kullanım formu, tüm merkezler tarafından, aynı gün içinde, antifungal kullanan tüm hastalar için, nokta prevalans yöntemi ile dolduruldu, elde edilen veriler SPSS programı ile değerlendirildi. Bulgular: Toplam hasta sayısı 4969 idi. Hastaların 112(%2.2) ’si antifungal tedavi almaktaydı. Bu 112 hastanın verileri değerlendirildiğinde; antifungal kullanan hastaların 56 (%50)’sı hematoloji-onkoloji, 20 (%17,8)’si yoğun bakım (YB), 23 (%20,5)’ü dahili bilimler ve 13 (%11,6)’ü cerrahi bilimlerde izlenmekteydi. En sık kullanılan antifungal flukonazol [44(%39,3)] olup %34.1’i profilaksi amacı ile kullanılmaktaydı. Tedavilerin %38’i hedefe yönelik, %26.8’i ampirik ve %18,8’i preemptif olarak tanımlanmıştı. Yattığı kliniğe göre tedavi endikasyonları değerlendirildiğinde en çok pre-emptif antifungal kullanımı hemato-onkoloji kliniğinde %71.4 (15/21) görülürken ampirik tedavi en çok yoğun bakımlarda %50 olmuştur. Sonuç: Çalışmamızda antifungal tüketim oranı %2.2 olup, antifungal ajanlar daha çok hematoloji ve dahili birimlerde kullanılmıştır. Antifungal tedaviye başlama nedeni en fazla 'kanıtlanmış mantar infeksiyonu' olarak gözlenmiştir. En sık izole edilen patojenler Candida türleri olmasına rağmen, antifungal ajan seçimi hastanın yattığı kliniğe bağlıdır. Antifungal tüketim açısından yedi merkez arasında anlamlı fark gözlenmemiştir. Bu durum ülkemizdeki antifungal kullanımı politikası ile açıklanabilir. Bu sonuçlara bağlı olarak her hastane kendi verilerini izlemelidir ve izole edilen fungal patojenlere göre antifungal tedavi politikası geliştirilmelidir.